🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Metastatic Colorectal Cancer
Clinical trial register · France

Metastatic Colorectal Cancer Trials in France, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9693 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:56 UTC
9693
Studies in scope
all four open statuses
6031
Recruiting now
open to new participants
1035
Lead sponsors
across recruiting studies
Top sites
Lyon 12 Besançon 12 Montpellier 10 Paris 10 Lille 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
UNICANCER5 GERCOR - Multidisciplinary Oncology Cooperative Group5 Centre Hospitalier Universitaire de Besancon2 Institut du Cancer de Montpellier - Val d'Aurelle1 EMD Serono Research & Development Institute, Inc.1
Site location
Lyon12 Besançon12 Montpellier10 Paris10 Lille8
All 54 locations
Target enrolment
to

Metastatic Colorectal Cancer trials in France

26 of 9693 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Not yet open
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
NCT07359456Metastatic Colorectal Cancer
DrugsFOLFIRI Protocol·Ivonescimab·Bevacizumab
UNICANCER
Phase 2
130
Auxerre, Beuvry, Caen, Calais, Compiègne, Coudekerque-Branche, Lille, Lyon
2026-08-31
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Bevacizumab
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Lille, Saint Priest En Jarez, Lyon, Paris
2026-05-06
Not yet open
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
NCT07071844Metastatic Colorectal Cancer
DrugsLonsurf·Avastin·Trifluridine/Tipiracil·Bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2
162
Amiens, Besançon, Caen, La Roche-sur-Yon, Lille, Lyon, Paris, Pessac
2025-09
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Panitumumab·Leucovorin·Fluorouracil
AbbVie
Phase 2
390
Lille, Poitiers, Paris
2025-04-24
Recruiting
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
NCT06245356Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
DrugsLonsurf·Panitumumab·Trastuzumab·Nivolumab
UNICANCER
Phase 2
73
Amiens, Angers, Avignon, Besançon, Cholet, Dijon, Lyon, Montpellier
2025-03-21
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Bordeaux, Marseille, Montpellier, Poitiers, Saint-Priez En Jarez, Villejuif
2025-03-12
Recruiting
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
NCT06425133Metastatic Colorectal Cancer
DrugRegorafenib
Centre Hospitalier Universitaire de Besancon
Phase 2
174
Auxerre, Besançon, Colmar, Dijon, Metz, Montbéliard, Montpellier, Reims
2024-07-19
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
DrugsBevacizumab-awwb·Mvasi·Sotorasib·Panitumumab
Amgen
Phase 3
450
Clermont-Ferrand, Créteil, Dijon, Lyon, Montpellier, Nice, Paris, Pessac
2024-07-17
Recruiting
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
NCT05787197Metastatic Colorectal Cancer, Circulating Tumor DNA
GERCOR - Multidisciplinary Oncology Cooperative Group
Observational
232
Besançon, Bordeaux, Lille, Lyon, Paris, Pessac, Poitiers, Rouen
2024-01-09
Recruiting
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NCT05639413Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
UNICANCER
Not applicable
400
Avignon, Bayeux, Beauvais, Bordeaux, Bourg-en-Bresse, Cahors, Calais, Caluire-et-Cuire
2023-07-24
Recruiting
Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer
NCT05299840Metastatic Colorectal Cancer
Oncomedics
Not applicable
450
Marseille
2023-06-07
Recruiting
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
NCT05462613Metastatic Colorectal Cancer
DrugsFolfiri·Regorafenib·Folfox·Aspirin
Centre Hospitalier Universitaire de Besancon
Phase 2/3
446
Besançon, Clermont-Ferrand, Créteil, Dijon, Lyon, Montbéliard, Montpellier, Mulhouse
2023-05-09
Active, closed
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
NCT05608044Metastatic Colorectal Cancer
DrugsBalstilimab·Botensilimab
Agenus Inc.
Phase 2
234
Besançon, Marseille, Paris, Poitiers, Villejuif
2022-11-30
Active, closed
Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
NCT05201352Metastatic Colorectal Cancer
DrugTrifluridine/Tipiracil
Centre Georges Francois Leclerc
Phase 1/2
160
Dijon, Angers, Avignon, Besançon, Bordeaux, Carcassonne, Clermont-Ferrand, Levallois-Perret
2022-10-13
Not yet open
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
NCT05531045Metastatic Colorectal Cancer
Assistance Publique - Hôpitaux de Paris
Observational
222
Paris
2022-09
Recruiting
TARGETed Therapy Drug MONITOring in DIGestive Oncology
NCT05443087Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST
UNICANCER
Not applicable
330
Amiens, Auxerre, Avignon, Bayeux, Clermont-Ferrand, Clichy, Dijon, Évreux
2022-08-29
Active, closed
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446Metastatic Colorectal Cancer
DrugsEncorafenib·Cetuximab·Pembrolizumab
Pfizer
Phase 2
108
Paris, Clermont-Ferrand, Montpellier
2022-07-11
Recruiting
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
NCT05310643Metastatic Colorectal Cancer
DrugsYervoy·Opdivo·Ipilimumab·Nivolumab
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2
30
Besançon, Bordeaux, Lille, Limoges, Lyon, Montpellier, Nice, Paris
2022-05-05
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
DrugsAdagrasib·Erbitux·MFOLFOX6·Folfiri
Mirati Therapeutics Inc.
Phase 3
461
Chambray-lès-Tours, Avignon, Besançon, Bordeaux, Brest, Dijon, Lille, Lyon
2021-06-24
Active, closed
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
NCT04166604Metastatic Colorectal Cancer
DrugsLonsurf·Trifluridine/Tipiracil
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2
176
Amiens, Angers, Besançon, Beuvry, Bordeaux, Chauny, Compiègne, Coudekerque-Branche
2020-05-20
Active, closed
A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
NCT04188145Metastatic Colorectal Cancer
DrugsFluoropyrimidine·Bevacizumab
Centre Hospitalier Universitaire Dijon
Phase 3
400
Dijon
2020-01-27
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
DrugsLeucovorin·Fluorouracil·Ipilimumab·Cetuximab
Bristol-Myers Squibb
Phase 3
839
Limoges, Lille, Bayonne, Besançon, Lyon, Marseille, Montpellier, Nantes
2019-08-05
Active, closed
QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.
NCT03828227Elderly Patients, Metastatic Colorectal Cancer, Quality of Life
DrugsAvastin·Capecitabine·Bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3
49
Abbeville, Amiens, Beauvais, Boulogne-sur-Mer, Cannes, Compiègne, Creil, Créteil
2019-06-14
Active, closed
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
NCT03869892Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Capecitabine
Institut de Recherches Internationales Servier
Phase 3
856
Avignon, Besançon, Brest, Lyon, Montbéliard, Nice, Paris, Pessac
2019-03-21
Active, closed
Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy
NCT03908788Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Not applicable
130
Montpellier
2018-07-26
Active, closed
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
NCT02980510Metastatic Colorectal Cancer
UNICANCER
Phase 2
219
Avignon, Lyon, Montpellier, Nancy, Nîmes
2016-12
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-france/condition/metastatic-colorectal-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,693 studies in total at the last sync on 26 Sep 2026, 19:56 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies listing the condition Metastatic Colorectal Cancer.

How many Metastatic Colorectal Cancer trials are recruiting in France?

12 of the 26 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:56 UTC sync. A further 3 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Metastatic Colorectal Cancer), 26 studies
PhaseStudiesRecruitingShare
Phase 211542.3%
Phase 37226.9%
Not applicable4315.4%
Observational217.7%
Phase 1/2103.8%
Phase 2/3113.8%

Most active sponsors

Lead sponsors with the most studies (Metastatic Colorectal Cancer)
Lead sponsorStudiesRecruiting
GERCOR - Multidisciplinary Oncology Cooperative Group52
UNICANCER53
Centre Hospitalier Universitaire de Besancon22
AbbVie11
Agenus Inc.10
Amgen11
Assistance Publique - Hôpitaux de Paris10
AstraZeneca11
Bristol-Myers Squibb10
Centre Georges Francois Leclerc10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.